An observational study in Attention Deficit Disorder With Hyperactivity (ADHD) and Attention Deficit Disorder (ADD), sponsored by Onovis Augenpraxis. Not yet recruiting at 1 site in Switzerland. Open to participants aged 8 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Onovis Augenpraxis · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland — 5 open to participants now, 6 under way, 1 of them phase 3. Attention Deficit Disorder with Hyperactivity · Switzerland.
Among the 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland, this one is one of 4 that started in 2025, is one of 4 observational ones, and was the 16th registered.
1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →5 of the 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland are open now. Recruiting first, the newest first:
Luzerner Kantonsspital · Sites in Switzerland
Ages 18+
Stefan Lakämper · Sites in Switzerland
Ages 10+
Stéphanie Baggio · Sites in Switzerland
Ages 18–65
Nader Perroud · Sites in Switzerland
Ages 18–50 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 8 Years to 16 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 5
First in 2006; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 133 across 331 observational studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 80 across the 14 interventional studies, 75 across the 4 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Onovis Augenpraxis as lead sponsor.
Onovis Augenpraxis has 1 study filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Attention Deficit Hyperactivity Disorder (ADHD) affects more than 5 % of children and adolescents, with a globally increasing prevalence. The condition imposes a significant burden on affected individuals, their families, and healthcare systems. Early and accurate diagnosis is crucial to ensure timely therapeutic and educational interventions. However, current diagnostic practices rely heavily on clinical interviews and behavioral observations, which are inherently subjective and resource-intensive.
There is a growing need for objective diagnostic tools that can complement or even partially replace current clinical assessments. One promising approach involves eye-tracking technology, as ADHD is associated with altered oculomotor control and attention-related neural circuits. These changes may be reflected in measurable eye movement parameters, including saccadic latency and fixation stability.
This clinical investigation uses a certified, CE-marked medical eye-tracking device (neos™) to assess whether specific eye movement parameters can serve as objective biomarkers for ADHD. Although the device was originally designed to assess visual pathway integrity, it also captures parameters related to attention and executive function through standardized protocols. The test is examiner-independent, non-invasive, and takes approximately 10 minutes.
The study is observational and non-interventional, involving two groups of participants aged 8 to 16: 50 children with a clinically confirmed diagnosis of ADHD and 50 age-matched non-ADHD controls. All participants will complete a single neos™ eye-tracking assessment.
The primary hypothesis is that children with ADHD will demonstrate greater variability in saccadic latency and a higher frequency of large saccades (> 3°) during fixation compared to controls. These differences will be analyzed as potential diagnostic biomarkers. Diagnostic accuracy will be evaluated using receiver operating characteristic (ROC) analysis, with sensitivity, specificity and area under the curve (AUC) values reported.
Secondary hypotheses include:
Oculomotor parameters derived from the neos™ system can distinguish between ADHD subtypes (predominantly inattentive, hyperactive-impulsive and combined).
Combined oculomotor metrics correlate with ADHD symptom severity, potentially enabling a quantitative assessment of disease burden.
The results of this study could pave the way for the clinical adoption of objective, scalable and rapid diagnostic tools for ADHD. Beyond clinical use, such tools may also be adapted for population screening, telemedicine or integration into consumer-grade technologies such as virtual reality headsets. By validating a market-approved device for a new mental health indication, this study represents a critical step toward bridging research and clinical application in ADHD diagnostics.
Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders in children and adolescents. It is estimated that over 5 % of young people worldwide are affected, with numbers rising in many countries. ADHD can cause serious difficulties in everyday life - at school, at home and in social settings. Children with ADHD often struggle with attention, impulsivity and hyperactivity. If not recognized and treated early, these challenges can persist into adolescence and adulthood, affecting academic success, social relationships and mental health.
A timely and accurate diagnosis is therefore essential. However, diagnosing ADHD is not straightforward. Currently, it relies mainly on interviews with parents and children, behavioral observations and standardized questionnaires. While these methods can be effective, they are also subjective. The process often depends on how clearly the symptoms are described, how experienced the clinician is and how much time is available for assessment. This can lead to uncertainty or delays in diagnosis, especially in borderline or complex cases.
To improve this situation, researchers are exploring new ways to make the diagnosis of ADHD more objective, faster and easier to reproduce. One promising tool is eye-tracking - a method that measures how a person's eyes move while they look at specific images or follow visual targets on a screen. Scientific studies have shown that people with ADHD tend to have different patterns of eye movement, especially when it comes to focus, reaction time, and maintaining attention.
In this study, we use a medically certified device called neos™, which is designed to record and analyze eye movements in a highly accurate and standardized way. The neos™ system is already approved for clinical use in Europe for examining the visual system, but in this investigation, it is being tested for a new purpose: supporting the diagnosis of ADHD. The test is short (about 10 minutes), non-invasive and does not require verbal responses or physical interaction. It is fully automated and can be performed in a clinic by non-specialist staff.
The study will include 100 children between the ages of 8 and 16. Half of the participants will have a prior, clinically confirmed diagnosis of ADHD made by a specialist (such as a pediatrician, child neurologist or neuropsychologist). The other half will be age-matched children without ADHD. All participants will complete the same neos™ eye-tracking assessment.
The main goal of the study is to find out whether specific eye movement parameters - especially the variability in how fast the eyes move (saccadic latency) and the number of small, rapid eye movements during fixation - can reliably distinguish between children with and without ADHD. The idea is that children with ADHD may show more irregularities or signs of reduced visual focus during the test. These measurable differences could serve as biomarkers, which are objective signs that help confirm a diagnosis.
In addition to the main analysis, the study will also look at whether these eye movement patterns can help:
to differentiate between the three subtypes of ADHD (inattentive, hyperactive-impulsive, and combined)
and estimate the severity of symptoms, potentially providing a new way to monitor treatment response over time.
Importantly, this is not a treatment study. The children will not receive medication or therapy. The study only involves a single, short eye-tracking test that is safe and well-tolerated.
If the results of the study are promising, the findings could help bring a new, objective tool into routine ADHD diagnostics. Because the neos™ device is already approved and available on the market, such a test could be implemented quickly in clinical settings. In the future, similar technology could even be adapted for screenings in schools, remote assessments via telemedicine or even self-monitoring with VR headsets, making ADHD diagnostics more accessible and scalable worldwide.
By making the diagnostic process more objective and less dependent on clinical interpretation alone, this study hopes to contribute to earlier and more accurate diagnoses-and ultimately better outcomes for children living with ADHD.
The study population consists of children aged 8 to 16 years. Two groups will be included: children with a clinically confirmed diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) and age-matched children without ADHD. Participants will be recruited from pediatric and ophthalmologic clinics. Both male and female children are eligible. Informed consent will be obtained from participants and/or their legal guardians.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the ADHD group:
For the control group (non-ADHD):
Exclusion Criteria:
For both groups:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ADHD
Control Children
Saccade frequency during fixation
Number of saccades (eye movements \> 3°) made during a fixation task. This frequency is hypothesized to be higher in children with ADHD than in controls.
Time frame: Baseline
Variability of saccadic latency
Variability in the time it takes for participants to initiate saccadic eye movements in response to visual stimuli. This parameter is expected to be higher in children with ADHD compared to controls.
Time frame: Baseline
Sensitivity and Specificity of Composite Oculomotor Biomarker for ADHD Diagnosis
Diagnostic sensitivity and specificity of a composite oculomotor biomarker derived from variables predictive of ADHD. Thresholds for individual parameters (e.g. saccadic latency variability \> 110 ms, saccade frequency during fixation \> 10/minute) will be based on literature and refined using internal study data prior to confirmatory analysis. Thresholds and analysis procedures will be pre-specified in the Statistical Analysis Plan.
Time frame: At completion of baseline assessment (Day 0)
Discrimination Between ADHD Subtypes Using Multivariable Model Based on neos™ Eye-Tracking Parameters
A multivariable model based on neos™ eye-tracking parameters will be used to distinguish between the three ADHD subtypes: predominantly hyperactive-impulsive, predominantly inattentive and combined subtype. The model will incorporate all available neos™ eye-tracking data. Subtype classification performance (e.g. accuracy, sensitivity and specificity) will be evaluated based on internal validation procedures.
Time frame: At the end of data collection and prior to final analysis (estimated Month 12)
Correlation of Disease Severity with Oculomotor Biomarker for ADHD Severity Assessment
Disease severity in ADHD will be assessed in relation to a combined analysis of ocular motor parameters obtained via neos™ eye-tracking. The goal is to establish a new quantitative biomarker for ADHD severity. The correlation between oculomotor metrics and standardized clinical severity ratings (e.g. ADHD symptom scales) will be evaluated.
Time frame: Assessed at baseline visit (Day 0) - if everything is recorded
Plan to share: Undecided
Start is estimated for Sep 2025; primary completion for Jan 2026, 4 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →